Gland Pharma , a leading injectable-focused pharmaceutical company, has announced strong financial results for the first quarter. The company reported a significant 50% year-on-year increase in Profit After Tax (PAT) and achieved EBITDA breakeven for its Cenexi operations.

Financial Highlights

• Revenue from operations grew by 7% year-on-year to ₹15,056.00 million
• EBITDA increased by 39% year-on-year to ₹3,678.00 million
• EBITDA margin expanded by 549 basis points to 24%
• PAT surged by 50% year-on-year to ₹2,155.00 million
• PAT margin improved by 405 basis points to 14%

Operational Performance

The company's base business (Gland) showed steady growth with a 3% year-on-year increase in revenue to ₹10,409.00 million. The EBITDA for this segment rose by 22% to ₹3,592.00 million, with the EBITDA margin expanding to 35%.

Cenexi, Gland Pharma's European subsidiary, achieved a significant milestone by reaching EBITDA breakeven this quarter. The segment reported revenue of €48 million (₹4,648.00 million), marking a 20% year-on-year growth.

Geographic Performance

R&D and Product Pipeline

Gland Pharma continued to invest in research and development, with R&D expenses of ₹460.00 million, representing 4.4% of revenue. The company made significant progress in its product pipeline:

• Launched 12 new molecules in regulated markets
• Filed one ANDA and received approval for nine in the quarter
• Cumulative ANDA filings in the U.S. reached 372, with 325 approved and 47 pending
• Advanced its complex injectables pipeline with six products already launched and three more in line for approval

Strategic Initiatives

The company is focusing on several key areas for growth:

1. GLP-1 Expansion: Launched Liraglutide in the UK and Australia, with plans to increase GLP-1/Pen/cartridge capacity from 40 million to 140 million units.

2. Ready-to-Use (RTU) Bags: Filed one RTU infusion bag, bringing the total to 20 RTU products filed in the USA (14 approved). Ten additional products are under development.

3. Co-development Partnerships: 15 products are in co-development, with commercialization expected to begin in FY28.

4. Cenexi Integration: Streamlining operations and optimizing costs at the European facilities, with new product transfers and capacity expansions underway.

Management Commentary

Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, "We're off to a positive start this year with growth in revenue and a significant jump in profitability, driven by strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing as we strengthen our capabilities, add new capacity, and boost R&D with complex products and key partnerships."

Mr. Shyamakant Giri, Chief Executive Officer, added, "This quarter's performance, with improved margins and Cenexi achieving EBITDA breakeven, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth."

Gland Pharma's strong quarterly results demonstrate the company's resilience and strategic focus on high-value injectables and geographic expansion. With ongoing investments in R&D, manufacturing capabilities, and strategic partnerships, the company appears well-positioned for continued growth in the global pharmaceutical market.

Gland Pharma , a leading generic injectable-focused pharmaceutical company, has announced robust financial results for the first quarter, ending June 30.

Key Financial Highlights

• Revenue from operations increased by 7% year-on-year to ₹15,056.00 million
• Gross profit margin expanded to 65% from 60% in the same quarter last year
• EBITDA surged by 39% year-on-year to ₹3,678.00 million
• EBITDA margin improved significantly to 24% from 19% in the same quarter last year
• Profit After Tax (PAT) grew by an impressive 50% year-on-year to ₹2,155.00 million
• PAT margin increased to 14% from 10% in the same quarter last year

Performance Breakdown

The company's base business (Gland) showed steady growth with a 3% year-on-year increase in revenue to ₹10,409.00 million. The EBITDA for this segment rose by 22% to ₹3,592.00 million, with the EBITDA margin expanding to 35% from 29% in the previous year.

Cenexi, Gland Pharma's European subsidiary, achieved a significant turnaround by reaching EBITDA breakeven this quarter. The segment reported a 20% year-on-year revenue growth to €48.00 million (₹4,648.00 million).

Geographical Performance

Operational Highlights

• R&D Expenses: The company invested ₹460.00 million in R&D, representing 4.4% of revenue.
• New Launches: 12 new molecules were introduced in regulated markets, including Colistimethate, Epinephrine, and Liraglutide.
• ANDA Filings: One new ANDA was filed, and nine were approved, bringing the cumulative total to 372 ANDA filings in the U.S. (325 approved, 47 pending).
• GLP-1 Expansion: Liraglutide was launched in the UK and Australia, with plans to increase GLP-1/Pen/cartridge capacity from 40 million to 140 million units.

Management Commentary

Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, "We're off to a positive start this year with growth in revenue and a significant jump in profitability, driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing, and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships."

Mr. Shyamakant Giri, Chief Executive Officer, added, "This quarter's performance, with improved margins and Cenexi achieving EBITDA breakeven, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth."

Future Outlook

Gland Pharma continues to focus on expanding its complex injectables pipeline, with six products already launched and three more in line for approval. The company is also advancing its co-development partnerships, with 15 products in development and commercialization anticipated to begin in FY28.

The company's strategic investments in R&D, adherence to global quality standards, and capacity expansion initiatives position it well for future growth and market expansion in the injectable pharmaceuticals segment.